Trial · NCT00503581
Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
NCT00503581, Phase 2, Terminated, Gynecologic Oncology Group; results first posted 2020-10-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia. Trials, record NCT00503581. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00503581
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
- NCT number
- NCT00503581
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Gynecologic Oncology Group
- Conditions
- High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer
- Interventions
- Biopsy, Laboratory Biomarker Analysis, Megestrol Acetate, Pharmacological Study, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- First posted
- 2007-07-19
- Last updated
- 2020-11-03
- Results first posted
- 2020-10-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Who Experience a Response as Determined by a Central Blinded Review of the Three Post Treatment Endometrial | Up to 12 months after completion of treatment | Treated and eligible participants. This study had 0 participants that completed treatment, therefore no analysis was done. Study closed prior to completion. Central blinded review was not performed for any participants in the study. |
| Secondary | Change in Quality of Life (QOL) Evaluated Using the Hospital Anxiety and Depression Scale (HADS) and the Two Items on Bleeding and Weight Gain | Baseline to up to 12 months | Eligible and Treated patients. This study had 0 participants that completed study. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Who Experience a Response as Determined by a Central Blinded Review of the Three Post Treatment Endometrial | Up to 12 months after completion of treatment | Treated and eligible participants. There were none. | ||
| SECONDARY | Change in Quality of Life (QOL) Evaluated Using the Hospital Anxiety and Depression Scale (HADS) and the Two Items on Bleeding and Weight Gain | Baseline to up to 12 months | Eligible and treated patients. This study was closed before subjects could complete evaluation. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Regimen 1 (Megestrol Acetate, Surgery) | 3 | |
| Overall Study | STARTED | Regimen 2 (Megestrol Acetate, Surgery) | 4 | |
| Overall Study | STARTED | Regimen 3 (Surgery/Biopsy) | 2 | |
| Overall Study | COMPLETED | Regimen 1 (Megestrol Acetate, Surgery) | 0 | |
| Overall Study | COMPLETED | Regimen 2 (Megestrol Acetate, Surgery) | 0 | |
| Overall Study | COMPLETED | Regimen 3 (Surgery/Biopsy) | 0 | |
| Overall Study | NOT COMPLETED | Regimen 1 (Megestrol Acetate, Surgery) | 3 | |
| Overall Study | NOT COMPLETED | Regimen 2 (Megestrol Acetate, Surgery) | 4 | |
| Overall Study | NOT COMPLETED | Regimen 3 (Surgery/Biopsy) | 2 |
Source ClinicalTrials.gov
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Weight Gain | General disorders | Regimen 1 (Megestrol Acetate, Surgery) | 1 | 3 | |
| other | Weight Gain | General disorders | Regimen 2 (Megestrol Acetate, Surgery) | 0 | 4 | |
| other | Weight Gain | General disorders | Regimen 3 (Surgery/Biopsy) | 0 | 2 | |
| other | Fatigue | General disorders | Regimen 1 (Megestrol Acetate, Surgery) | 2 | 3 | |
| other | Fatigue | General disorders | Regimen 2 (Megestrol Acetate, Surgery) | 1 | 4 | |
| other | Fatigue | General disorders | Regimen 3 (Surgery/Biopsy) | 0 | 2 | |
| other | Hemorrhage, Gu - Vagina | Vascular disorders | Regimen 1 (Megestrol Acetate, Surgery) | 0 | 3 | |
| other | Hemorrhage, Gu - Vagina | Vascular disorders | Regimen 2 (Megestrol Acetate, Surgery) | 1 | 4 | |
| other | Hemorrhage, Gu - Vagina | Vascular disorders | Regimen 3 (Surgery/Biopsy) | 0 | 2 | |
| other | Hemorrhage, Gu - Uterus | Vascular disorders | Regimen 1 (Megestrol Acetate, Surgery) | 0 | 3 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Regimen 1 (Megestrol Acetate, Surgery) | 0 | 3 |
| Total, all-cause mortality | Regimen 2 (Megestrol Acetate, Surgery) | 0 | 4 |
| Total, all-cause mortality | Regimen 3 (Surgery/Biopsy) | 0 | 2 |
| Total, other adverse events | Regimen 1 (Megestrol Acetate, Surgery) | 2 | 3 |
| Total, other adverse events | Regimen 2 (Megestrol Acetate, Surgery) | 2 | 4 |
| Total, other adverse events | Regimen 3 (Surgery/Biopsy) | 0 | 2 |
| Total, serious adverse events | Regimen 1 (Megestrol Acetate, Surgery) | 0 | 3 |
| Total, serious adverse events | Regimen 2 (Megestrol Acetate, Surgery) | 0 | 4 |
| Total, serious adverse events | Regimen 3 (Surgery/Biopsy) | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA101165 | GYNECOLOGIC ONCOLOGY GROUP | DISAIA, PHILIP J. | GYNECOLOGIC ONCOLOGY GROUP | NATIONAL CANCER INSTITUTE | 2003 to 2014 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00503581
GET https://conductscience.org/api/trials/v1/NCT00503581/events?page=2